Macro analysis
€65–130 million per year in a sector without its own DBC-code, without an official total, and with a waiting list that has itself become an economic instrument.
A treatment error without a budget line
Search the Dutch national budget for "transgender care" and you'll find almost nothing. Yet €65–130M per year flows through the sector. It is a protocol error that has, over fifteen years, embedded itself in the structure of Dutch healthcare finance — invisible, fragmented, and therefore difficult to correct.
The four payers
Who pays? In descending order:
1. Health insurers (Zvw)
~80%
€55–100M/year via premiums of all Dutch insured. Four large insurers (Zilveren Kruis, VGZ, CZ, Menzis) carry ~85%. Collective solidarity for an unproven treatment.
2. Patients themselves
~10–15%
Own-risk excess, non-contracted care, facial feminisation (FFS), supplementary breast augmentation, hair removal — often partial own payment.
3. Municipalities (Youth Act)
~5–10%
For minors <18. Decentralisation effect: costs spread across 342 municipalities, not uniformly registered — exactly what makes structural monitoring impossible.
4. National government
<5%
Direct subsidies (breast prostheses €2.8M/year through 2027, programme subsidies). Financially marginal — but politically the most visible, and first under the budget axe.
Four scenarios to 2040 — SiRM
SiRM (March 2023, for ZonMw/VWS) developed four scenario models. The Cass doctrine is hidden inside scenario D.
| Scenario | 2025 | 2031 | 2040 |
|---|---|---|---|
| A — Demographic | €80M | €90–100M | €110–130M |
| B — Strong growth | €80M | €120–160M | €200+M |
| C — Shift (non-binary) | €80M | €85–105M | €100–130M |
| D — Decline (Cass effect) | €80M | €60–75M | €50–70M |
SiRM concludes that temporary catch-up capacity is needed in every scenario: €30–80M additional over 2025–2031 — a substantial amount, regardless of whether expansion is desirable.
The waiting-list paradox
Six-year waiting lists look like a crisis. Macro-economically, they are not — for the financiers:
- Those waiting consume no expensive somatic care during that period
- They do consume indirect care (GP, secondary mental health, self-medication — Transvisie 2016: 26% trans-women / 7% trans-men sourced hormones through informal channels)
- Some drop out, change their mind, or arrange things differently
For insurers and the short-term VWS budget, a long waiting list is cheaper than capacity expansion. SiRM implicitly noted that providers have little financial incentive to shorten the waiting list. This explains why VWS has been setting 50%-reduction targets since 2018 while waiting times in the same period grew by more than 50%.
The hidden counter-bill
Against the short-term savings stand costs elsewhere in society — invisible in healthcare figures:
- Lost work — job loss and study delay among those waiting (SiRM, Radboud document significant effects)
- Mental health — secondary depression, anxiety, suicidality
- UWV (benefits agency) — sick leave and disability
- Municipalities — WMO applications (social support)
- Society — self-medication and its health consequences
Rough estimate: €20–50M/year on top of direct care costs, spread across budgets without a "transgender" label. The other side: many of these costs persist after transition — Cass findings show that psychological problems and work loss do not structurally improve after medical pathways.
Gender care in the total healthcare field
| Sector | NL revenue |
|---|---|
| Total Dutch healthcare spending 2025 | ~€130bn |
| Medical specialist care (Zvw) | ~€34bn |
| Plastic surgery (insured) | ~€500M |
| IVF care Netherlands | ~€100M |
| Gender care (total) | €65–130M |
In financial terms small — comparable to IVF. In political and symbolic weight, much larger. No other medical sector is so directly influenced by public debate.
The Netherlands' position
The Netherlands sits between two poles:
🇬🇧 UK + 🇸🇪 🇫🇮 🇩🇰
Cass Review, SBU, COHERE. NHS gender identity clinics closed. Puberty blockers outside research setting prohibited. Turn towards caution.
🇳🇱 Netherlands
Comprehensive insured coverage + capacity limitation through waiting lists. Defensive maintenance of the original protocol — while the rest of the world pivots.
🇺🇸 USA
Fully private. $25,000–150,000 per person. Advocacy groups see this as the expansion model NL should move towards.
Political pressure from JA21, BBB, NSC, SGP and parts of VVD is building to follow the British model. Advocacy organisations push towards the American availability model. The middle path is unstable.
Cass effect on the Dutch budget
The Cass Review has had no direct budget consequences in the Netherlands yet. But the political ammunition is accumulating:
- 2023–2024: JA21 + SGP parliamentary questions on the scientific basis of the Dutch Protocol
- VVD: concerns over "moving too quickly to medical specialist care" for adolescents
- February 2024: four transgender lawsuits filed — outcome unknown
- October 2024: Agema cancels breast prostheses subsidy
- 2025–2026: new cabinet expected to demand recalibration of the Quality Standard Somatic
Under a UK-style course: a fall of €15–30M/year in the youth segment (15–25% of total). For those earning from youth pathways — Amsterdam UMC, UMCG, Radboud, Mutsaersstichting — that is the threshold at which the business model comes under pressure.
Conclusion
Dutch gender care is small in absolute terms (€65–130M) but systemically interesting. It is the healthcare sector that is least about healthcare and most about choices society wants to make.
To predict the future, don't look at medical developments — these have been relatively stable since the Dutch Protocol of 2006. Look at parliamentary papers, VWS budget letters, and statements from insurers. The financial structure (no DBC, four payers, fragmented registration) makes correction technically difficult and politically easy to postpone.
As long as the Netherlands publishes no independent evidence review — uniquely so among the originators, while the Cass-countries did — the €65–130 million will continue to flow through the basic insurance package, year after year.
Related on this site
Sister sites
Sources
- SiRM, Uncertainty about demand for transgender care, catch-up capacity certainly needed, March 2023
- Radboud University / ZonMw, My gender, whose care?, February 2023
- KPMG Health for VWS, Design body transgender care, September 2023
- Dutch Health Care Institute, Package Agenda Appropriate Care 2023–2025
- Evaluation Subsidy Scheme breast prostheses trans-women (open.overheid.nl)
- Parliamentary papers 31016 nos. 346 + K; 36200-XVI no. 15; 31016 no. 365
- Spring Memorandum 2025; budget cut letter Minister Agema October 2024 (NOS)
- Vektis Open Data; NZa market scans MSZ and mental health
- Cass Review (NHS England, 2024); WPATH SOC 8; Amsterdam UMC response April 2024
- Transvisie 2016 (self-medication); Genderhealthcare capacity reports